Literature DB >> 2878937

Selective suppression of insulin-induced proliferation of cultured human hepatoma cells by somatostatin.

C K Chou, L T Ho, L P Ting, C P Hu, T S Su, W C Chang, C S Suen, M Y Huang, C M Chang.   

Abstract

The effects of somatostatin (SRIF), insulin, and triiodothyronine (T3) on the growth of human hepatoma cells were investigated on the well-differentiated human hepatoma cell line Hep3B. Results showed that both insulin and T3 can stimulate cell growth of serum starved Hep3B cells at physiological concentrations. SRIF alone showed little growth-promoting activity. When added concurrently with insulin, however, SRIF suppressed the insulin-induced cell proliferation in a dose-dependent manner. On the other hand, SRIF had no inhibitory effect on T3-induced cell proliferation. SRIF is labile in the medium, with a half-life of about 2 h during culture incubation. SRIF did not disturb the insulin binding to its surface receptors nor inhibit the insulin-dependent receptor kinase activity of Hep3B cells in vitro. These results suggest that postreceptor regulation may be involved. The selective suppression by SRIF of insulin-induced cell growth provides an unique approach to the study of insulin actions on proliferation of human hepatoma cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2878937      PMCID: PMC424015          DOI: 10.1172/JCI112780

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

Review 1.  Hormonal control of rat liver regeneration.

Authors:  H L Leffert; K S Koch; T Moran; B Rubalcava
Journal:  Gastroenterology       Date:  1979-06       Impact factor: 22.682

Review 2.  Thyroid hormone action at the cellular level.

Authors:  J H Oppenheimer
Journal:  Science       Date:  1979-03-09       Impact factor: 47.728

3.  Induction of deoxyribonucleic acid synthesis in the liver of the intact animal.

Authors:  J Short; R F Brown; A Husakova; J R Gilbertson; R Zemel; I Lieberman
Journal:  J Biol Chem       Date:  1972-03-25       Impact factor: 5.157

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects--a two-compartment open model.

Authors:  L T Ho; R L Chen; T Y Chou; J C Fong; P S Wang; C K Chou
Journal:  Clin Physiol Biochem       Date:  1986

6.  Functional subdivision of islets of Langerhans and possible role of D cells.

Authors:  L Orci; R H Unger
Journal:  Lancet       Date:  1975-12-20       Impact factor: 79.321

7.  Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Authors:  P Brazeau; W Vale; R Burgus; N Ling; M Butcher; J Rivier; R Guillemin
Journal:  Science       Date:  1973-01-05       Impact factor: 47.728

8.  Pancreatic and gastric somatostatin release in response to intragastric and intraduodenal nutrients and HCl in the dog.

Authors:  V Schusdziarra; V Harris; J M Conlon; A Arimura; R Unger
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

9.  Insulin--receptor interactions in adipose tissue cells: direct measurement and properties.

Authors:  P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1971-06       Impact factor: 11.205

10.  Regulation of hepatic regeneration in rats by synergistic action of insulin and glucagon.

Authors:  M L Bucher; M N Swaffield
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

View more
  10 in total

1.  Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells.

Authors:  Hendrik Reynaert; Krista Rombouts; Yutao Jia; Daniel Urbain; Nirjhar Chatterjee; Naoki Uyama; Albert Geerts
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

2.  Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.

Authors:  H Reynaert; K Rombouts; A Vandermonde; D Urbain; U Kumar; P Bioulac-Sage; M Pinzani; J Rosenbaum; A Geerts
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

3.  Cancer risk in patients with diabetes mellitus.

Authors:  H O Adami; J McLaughlin; A Ekbom; C Berne; D Silverman; D Hacker; I Persson
Journal:  Cancer Causes Control       Date:  1991-09       Impact factor: 2.506

4.  Somatostatin analogue (octreotide) inhibits bile duct epithelial cell proliferation and fibrosis after extrahepatic biliary obstruction.

Authors:  T F Tracy; A J Tector; M E Goerke; S Kitchen; D Lagunoff
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

5.  Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.

Authors:  Valter Donadon; Massimiliano Balbi; Pietro Casarin; Alessandro Vario; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

6.  Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China.

Authors:  Xu Li; Hongqin Xu; Yang Gao; Meng Pan; Le Wang; Pujun Gao
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 7.  Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.

Authors:  Shen Li; Antonio Saviano; Derek J Erstad; Yujin Hoshida; Bryan C Fuchs; Thomas Baumert; Kenneth K Tanabe
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241

Review 8.  Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma.

Authors:  Argyrios Periferakis; Georgios Tsigas; Aristodemos-Theodoros Periferakis; Ioana Anca Badarau; Andreea-Elena Scheau; Mircea Tampa; Simona Roxana Georgescu; Andreea Cristiana Didilescu; Cristian Scheau; Constantin Caruntu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-11-27       Impact factor: 2.916

Review 9.  Diabetes Mellitus and Risk of Hepatocellular Carcinoma.

Authors:  Xu Li; Xiaocong Wang; Pujun Gao
Journal:  Biomed Res Int       Date:  2017-12-12       Impact factor: 3.411

Review 10.  Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.

Authors:  Hendrik Reynaert; Isabelle Colle
Journal:  Int J Mol Sci       Date:  2019-09-27       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.